Training Example: Biose Industrie – Review the Data, Give Your Score & Compare to the Real AI Evaluation

[H1] Your microbiome partner
for health and well-being
Microbiome. Manufacturing. Mastered.
From strains to finished products, Biose Industrie manufactures microbiome solutions for pharmaceutical and non-pharmaceutical markets, supporting projects from development to commercial supply.
[H5] Biose
[H2] BIOSE INDUSTRIE
Biose Industrie is a specialised microbiome CDMO supporting biotechnology, pharmaceutical, and consumer-focused companies across Live Biotherapeutic Products (LBPs), Next-Generation Probiotics (NGPs), consumer health, consumer care, and cosmetics.
We combine deep aerobic and anaerobic microbiology expertise, industrial scale, and robust GMP quality systems to take projects from development to commercialisation.
[H5] Vision
[H2] Vision
Our vision is to build a future where the potential of micro-organisms strengthens and enhances health and well-being, across regulated pharmaceutical applications and everyday consumer solutions.
[H5] Identity
[H2] Identity
A pioneer in pharmaceutical microbiology since 1951, Biose Industrie operates two complementary businesses serving a wide range of industries:
[H3] CDMO Services
An international CDMO specialised in Live Biotherapeutic Products (LBPs) and Next-Generation Probiotics (NGPs), from process development to GMP drug product manufacturing.
[H3] Strains, Ingredients & Finished Products
Supplier of microbiome-based ingredients and finished products under private label for the health, nutrition, wellness, and cosmetic markets.
[H5] Mission
[H2] Mission
Our mission is to contribute to the success and satisfaction of our clients by delivering micro-organism-based solutions — ingredients, finished products, and dedicated developments — driven by scientific excellence, industrial performance, and anticipation of regulatory and market evolutions.
[H5] One-stop CDMO
[H2] Welcome to our one-stop CDMO
[IMG: A Microbiome Odyssey Across Asia in 10 days]
June 5, 2025
[H3] A Microbiome Odyssey Across Asia in 10 days
...Read More
[IMG: Next Generation Probiotics (NGPs) – The Next Era of Probiotics?]
April 15, 2025
[H3] Next Generation Probiotics (NGPs) – The Next Era of Probiotics?
...Read More
[IMG: Microbiome Wrapped 2024 – A Year in Review & What’s Next]
December 30, 2024
[H3] Microbiome Wrapped 2024 – A Year in Review & What’s Next
...Read More
[H2] Serious science. Real GMP.
A partner you can rely on — whatever your market.

[H1] About us
[H5] advantages
[H2] Why biose
Biose Industrie is the most experienced CDMO dedicated exclusively to microbiome therapeutics and next generation Probiotics
[H3] Key Advantages:
70+ years of GMP experience
Full DS + DP manufacturing under one roof
Commercial scale, 32,000 L fermentation capacity
US tech-transfer facility for rapid client onboarding
Long-term expertise in anaerobes, multi-strain programs, and LBPs
[H5] Activity
[H2] Company activity

[H2] Founded in 1951
Biose Industrie is the world leading CDMO for microbiome therapeutics and Next Generation Probiotics. Our facilities comprise a center of excellence of 52 000m2 based in Aurillac, France and an applied tech transfer laboratory in Boston, USA. We are capable of taking your laboratory strain from process development and scale-up to the delivery of GMP manufacturing services of both drug substance and drug product at clinical and commercial levels. We also finalize the secondary packaging and labelling of your products for shipment to your clinical trial distributor anywhere in the world. Biose Industrie : A real one-stop CDMO.
[IMG: Founded in 1951]
[H5] Values
[H2] Core values
Commitment
Agility
Responsibility
Expertise

[H2] Commitment
At Biose Industrie, Commitment is more than just a word – it’s our guiding principle. We understand the critical role we play in bringing life-saving therapies to patients worldwide. Every member of our team is deeply committed to excellence in everything we do, from developing innovative biopharmaceutical process solutions to delivering exceptional manufacturing services. Our unwavering dedication ensures that we meet and exceed the expectations of our clients and partners, making a meaningful impact on global healthcare.
[IMG: Commitment]
[H2] Agility
In the fast-paced biopharmaceutical industry, agility is paramount. At Biose Industrie, we embrace change as an opportunity for growth and innovation. Our agile approach enables us to quickly adapt to evolving market dynamics, regulatory requirements, and technological advancements. Whether it’s scaling up production to meet increased demand or pivoting our strategies in response to new developments, we remain agile and responsive, ensuring that we stay ahead of the game and deliver value to our clients.
[IMG: Agility]
[H2] Responsibility
As a trusted partner in the biopharmaceutical supply chain, Biose Industrie recognizes the immense responsibility we have to patients, healthcare providers, and the broader community. We hold ourselves to the highest standards of ethical conduct, environmental stewardship, and social responsibility. Our commitment to responsible manufacturing practices, product quality, and regulatory compliance ensures the safety, effectivness, and reliability of the therapies we help bring to market. We are dedicated to making a positive impact on society and upholding the trust placed in us by our stakeholders.
[IMG: Responsibility]
[H2] Expertise
Expertise is the cornerstone of our success at Biose Industrie. With decades of collective experience in the biopharmaceutical industry, our team of experts possesses unparalleled knowledge, skills, and technical know-how. From process development and analytical testing to cGMP manufacturing and regulatory affairs, we leverage our expertise to deliver tailored solutions that meet the unique needs of each client. Our relentless pursuit of excellence drives continuous improvement and innovative solutions, positioning Biose Industrie as the leading CDMO in the biopharmaceutical sector.
[IMG: Expertise]
By embodying these values—commitment, agility, responsibility, and expertise—Biose demonstrates its dedication to advancing healthcare and improving patient outcomes. As we continue to grow and evolve, these values will remain at the core of everything we do, guiding our actions and shaping our future success.
[H5] Team
[H2] Business team
[H5] Adrien NIVOLIEZ
CBO
[H5] Rishi TRIVEDI
Business Development Director – US & India
[H5] Alexander LEPAGE
Business Develpment Director – Europe and LATAM
[H5] Richard ELLIS
Global Business Development Director – CDMO Services
[H5] Team
[H2] Management team
[H5] Adrien NIVOLIEZ
CEO
[H5] Samuel BRISSEZ
VP Process
[H5] Emmanuelle BARDET
VP Quality & QP
[H5] Caroline DAUSSET
VP Analytics
[H5] Bertrand CLAUX
VP Human Resources
[H5] Paul-Marie CHASSAING
VP Finance
[H5] Nadine DAOU
VP US Operations
[H5] History
[H2] Company History
[IMG: biose-background-violet]
[H4] 2023
Adrien NIVOLIEZ becomes the Chairman and CEO of BIOSE Industrie and the company continues as the world leading CDMO
[H5] 350 employees
[IMG: employees-biose-350-microbiote]
[H4] February 2023
BIOSE Industrie raises a joint investment of €80M by L-GAM and the French State through the French Tech Souveraineté scheme and creates 200 jobs
[IMG: investissement-biose-2023]
[IMG: employees-biose-150-microbiote]
[H5] 150 employees
[IMG: office-boston-usa-biose-industrie]
[H4] Septembre 2020
Creation of new offices in Boston, USA
[IMG: biose-industries-entreprise-laureate-2021]
[H4] 2021
BIOSE Industrie is granted €5M by the French State as part of the France Relance scheme
[IMG: catahy-capital-biose-aurillac-invests]
[H4] July 2020
With the support of Cathay Capital, BIOSE Industrie invests €40M in its Aurillac plant
[IMG: biose-background-jaune]
[H4] January 2020
BIOSE and BIOSE Industrie merge to become BIOSE Industrie
[IMG: employees-biose]
[H5] 60 employees
[H4] 2015
[IMG: biose-background-rose]
[IMG: adrien-nivoliez-biose-industrie]
[H4] 2017
Adrien NIVOLIEZ becomes the CEO of BIOSE Industrie
[IMG: biose-background-violet]
[H4] 2011
Creation of PROBIONIOV, a subsidiary of LYOCENTRE, with a new commercial department in Clermont-Ferrand and the R&D department in Aurillac
[H4] 2008
Creation of a Research and Development (R&D) department
[IMG: biose-background-jaune]
[H4] 1997
Acquisition of LYOCENTRE by Hubert DESJONQUERES, implementing a policy of commercial and industrial revitalization
[IMG: huber-desjonqueres-biose-lyocentre]
[IMG: biose-lyocentre-aurillac]
[H4] 2005-2007
Consolidation of the manufacturing facilities at the Aurillac plant
[IMG: stanislas-desjonqueres-lyocentre-ceo]
[H4] 2007
Stanislas DESJONQUERES becomes the CEO of LYOCENTRE
[IMG: biose-background-rose]
[H4] 1975
Creation of the Aurillac plant
[IMG: DEVELOPPEMENT-ST-SIMON-PLANT-BIOSE-LYOCENTRE]
[H4] 1958-1978
Development of the Saint-Simon plant
[IMG: CREATION-LYOCENTRE]
[H4] 1951
Creation of LYOCENTRE

[H3] by Richard Ellis
As all good adventures begin, mine started with… a delay. Toulouse to CDG went from “on time” to “technical difficulties” faster than failing to connect to the flight wifi, which meant I missed my original connection to Singapore. Grrh.
Thankfully, years of airline travel (and platinum status with Air France) have taught me to anticipate chaos. I phoned in a lifeline mid-delay and secured a seat on a later flight via Hong Kong. Crisis managed – sort of. I landed in Singapore fashionably late, just in time for my morning presentation at the Microbiome Business Collaboration event by Global engage. Nothing quite like going from jet bridge to spotlight with nothing but a power nap and a prayer.
Now, I’m not a natural-born for the conference as a non-scientist I have an imposter syndrome thing going on. Put me in a partner meeting or a business dinner and I’m at home. Put me on stage, sleep-deprived and sweating through Singapore’s 200% humidity index, and I’m… less at home. But with a deep breath and a mild existential crisis, I made it through. My talk on LBP & NGP development (featuring highlights on strain CMC development and production, and lessons from over 30 clinical and commercial projects) was well-received – or at least, no everybody got up and left mid-sentence.
The rest of the event was a rewarding blend of science, networking, and a solid reminder that the microbiome world never sleeps – even if I desperately needed to.
Some presentations that I found particularly insightful from this whirlwind of a trip include:
Bridgette Wilson, PhD – Dietary Impact on Gut Microbiome in Health and Gastrointestinal Disorders
Focusing on gastrointestinal disorders like IBS, Dr. Wilson’s presentation explored how diet shapes the gut microbiome. She explained that while a low FODMAP diet shows efficacy in managing IBS symptoms, it also depletes beneficial gut bacteria such as Bfidobacterium – leading to concerns about its long-term use. To address this, Dr Wilson explained different approaches including probiotic and prebiotic supplementation. Wilson showed that in one trial supplementation of a multi-strain probiotic increased numbers of Bifidobacterium species in patients on low FODMAP compared to the control – a positive result. However, prebiotic supplementation with B-GOS, while improving symptoms, did not prevent the loss. Wilson closed by emphasising the need for personalised dietary solutions for IBS and cautioned against long term low FODMAP use.
Prof. Maurice van Steensel – The Case for Selective Microbiome Control
Opening by describing the importance of the skin microbiome in maintaining skin health, Prof Steensel presented the case for selective anti-bacterials in managing acne and body odour. Steensel explained that existing treatments for skin dysbiosis wipe out all bacterial populations, not distinguishing between the helpful strains such as S. epidermis and the pro-inflammatory ones like C. acnes. To overcome this, Steensel’s company ArrowBiome are developing targeted solutions based on lysins. Steensel introduced SmartArrow™, a precision payload delivery system, and ArcherZyme™, an engineered lysin, designed to clear harmful bacteria without irritating the skin. Data presented indicated SmartArrow™ could achieve bacterial clearance at significantly lower concentrations than conventional products.
Cherry Li – Large-scale Skin Metagenomics Reveals Extensive Prevalence, Coordination, and Functional Adaptation of Skin Microbiome Dermotypes Across Body Sites
Presenting data from one of the largest studies to date on the skin microbiome, Cherry Li revealed that analysis of over 3,500 metagenomes from 200 healthy individuals across 18 body sites identified 17 distinct “dermotypes” – unique microbial community types. Interestingly, these dermotypes were not restricted to specific sites but were consistently observed across different regions of the body. Li highlighted that certain dermotypes were linked to increased skin sensitivity and itch, even in individuals without diagnosed skin conditions. Li closed by highlighting emphasising how these findings could lay the groundwork for personalised dermatological therapies based on dermotype, moving beyond the current one-size-fits-all approach.
Dr. Mrinmoy Mazumder – Harnessing Beneficial Plant-Associated Microbiomes to Enhance Crop Yield, Quality, and Climate Resilience
Dr. Mazumder presented his team’s work on designing microbial consortia to boost crop yield, quality, and climate resilience. Using advanced culturomics and genome modelling, his group developed bacterial consortia that enhanced traits such as drought tolerance, sulphur uptake, and pest resistance in Arabidopsis and Kai-lan. He also highlighted how root-derived volatile organic compounds (VOCs) can stimulate beneficial soil biofilms from a distance, expanding a plant’s microbial sphere of influence and promoting growth.
Jet lag in Asia is its own special kind of torture. When your body thinks it’s 2am and the conference coffee is doing nothing, all bets are off. That said, I made the most of my Saturday in Singapore: the National Museum (blessedly air-conditioned), followed by a bold but ill-advised venture through Chinatown and Little India. After being flambéed by the equatorial sun, I beat a strategic retreat to the hotel pool.
Sunday morning: off to Korea! It’s the Asian country I visit most, yet it never ceases to amaze me. The food is a masterclass in fermentation, the people combine warmth with relentless drive, and there’s a palpable scientific energy – especially when it comes to microbiology and the microbiome. Not surprising then that Korea has been home to over a dozen clinical LBP lines we’ve worked on at Biose in the past seven years.
This Korean leg of the journey was particularly fruitful: promising discussions with long-standing partners, new collaborations emerging, and some genuinely exciting developments I look forward to sharing soon.
From the heat of Singapore to the buzz of Seoul, this trip reminded me why we do what we do – and how far microbiome science has come, from petri dish to patient. And maybe, just maybe, I’m starting to get used to public speaking. (But let’s not get carried away.)
[H2] Related Posts
[IMG: Co-culture: the science behind efficient multi-strain bacterial manufacturing]
May 15, 2026
[H3]
Co-culture: the science behind efficient multi-strain bacterial manufacturing

The latest results in microbiome research are speaking
Read More
[IMG: Field Notes from Copenhagen: Our highlights from the 2026 Microbiome Times Partnering Forum Europe]
April 28, 2026
[H3]
Field Notes from Copenhagen: Our highlights from the 2026 Microbiome Times Partnering Forum Europe

By Jean-Baptiste Doucet  |  April 2026
Read More
[IMG: Bacterial count in next-generation probiotics: AFU technology]
March 3, 2026
[H3]
Bacterial count in next-generation probiotics: AFU technology

Classical methodologies and current limitations
Switching from
Read More

What are NGPs?
The International Scientific Association for Prebiotics and Probiotics defines probiotics as “Live microorganisms that, when administered in adequate amounts, confer a health benefit on the host.”1
Traditionally probiotic products have comprised a narrow spectrum of micro-organisms, mostly containing strains from the bifidobacterium or lactobacillus genera isolated from fermented foods.
Recently however, scientists have turned their attention to new species that could confer benefit to the host, with the novel organisms being referred to as “next generation probiotics” or NGPs. Species within this category include Eubacterium hallii, Faecalibacterium prausnitzii, Roseburia spp., Akkermansia muciniphila, and Bacteroides fragilis or they can be innovative engineered strains designed to perform a specific function. These strains are often sourced from the gut and are anaerobic by nature.
How do NGPs differ from existing probiotics?
Contrasted with traditional probiotics, NGP species have been identified for their specific health benefits and function. These functions include short-chain fatty acid production, intestinal barrier regulation and immune system modulation.
Some NGP spp. have been associated with disease states. For instance, in 2008 the Sokol lab documented a depletion of Faecalibacterium prausnitzii in the gut microbiome of Crohn’s disease patients, with its lower abundance being linked to a higher risk of clinical flare.2
The NGP Landscape
The newness of the NGP market makes it a very exciting area of microbiome research, forecasted to more than double in size from 231 million USD in 2025 to 486 million USD by 2032.3 Companies are utilizing the unique properties of NGPs to provide consumers and patients with novel health benefits.
Pendulum Therapeutics
Based in San Francisco and founded in 2012, Pendulum Therapeutics has raised $111M to date.4 Pendulum therapeutics offers a variety of OTC probiotics, all containing A. muciniphila as well as other NGP strains. Naturally occurring in the gut, A. muciniphila has been associated with improved metabolic health, including a reduction in obesity risk and an increase in heart health.5
In March 2024, they launched their GLP-1 Probiotic, consisting of the 2 NGP strains A. muciniphila and Clostridium butyricum.6 Pendulum reference various preclinical studies to support their claim that their GLP-1 Probiotic can upregulate GLP-1 secretion in the host. One such study found that a metabolite secreted by A. muciniphila increased GLP-1 secretion in mice. In unpublished company data, Pendulum also reports a dose-dependent increase of GLP-1 by Clostridium butyricum in a cell-based assay. The company is currently testing their GLP-1 probiotic in a clinical trial with completion expected in 2025.7 The company also has active trials examining the impact of their NGPs on bipolar disorder, and bone health.
The Akkermansia Company
Also leveraging the health benefits of A. muciniphila is the Akkermansia Company in Belgium. Founded in 2004, the company was founded on the discovery of A municinphila by Willem M. de Vos’ laboratory of Wageningen University and the Patrice Cani’s research from UCLouvain. To date it has raised $21.9M in funding.8 Notably, The Akkermansia Company utilise a proprietary pasteurised form of A. muciniphila, Akkermansia MucT. Their product “Healthy Weight” has been available in Europe since 2021 and launched into the US in June 2024.9
In 2019, a randomised double-blind study conducted by The Akkermansia Company, the Microbes4U® study, found pasteurized A. muciniphila improved insulin sensitivity, reduced insulinemia and reduced plasma total cholesterol compared to the placebo in human subjects – interestingly, only the pasteurised form led to reduced cholesterol versus the live form.10 Bolstering these findings, a paper in Nature identified that pasteurised Akkermansia better strengthened intestinal integrity and lipid metabolism than the live form in a tissue model. 11
ClostraBio
A spin-out from the University of Chicago, ClostraBio are developing an NGP for targeted delivery of butyrate to promote gut health and intestinal barrier integrity.   Butyrate is critical to gut homeostasis, as it serves as the primary carbon source for colonocytes and promotes barrier integrity by upregulating tight junction proteins12 and increasing mucin production13.   However, decreased butyrate levels have been observed in individuals afflicted with numerous chronic diseases12,14 as well as those consuming a Western diet15,16.   ClostraBio’s CLB101 is an NGP that has been shown to produce high levels of butyrate from fermentation of prebiotics as well as from the lactate and acetate excreted by common gut commensals like Bifidobacteria17.  Manufacture of CLB101 has been successfully scaled to commercial capacity with a planned product launch in 202518.
Florey Biosciences
Spun out from Cubillos-Ruiz’s research in the MIT and Wyss Institute lab of James Collins, Ph.D., Florey Biosciences are developing genetically engineered probiotics to improve human health. Their lead product FLR-101, consists of a food-grade yeast strain which produces an enzyme to degrade beta-lactam antibiotics – which represents approximately 50% of antibiotics used. Antibiotic consumption significantly disrupts the fragile balance of the gut microbiome, an inconvenient side-effect of a highly useful drug class. Florey aim to eliminate this side-effect by shielding the gut microbiome with the beta-lactam degrading effects of FLR-101. As the yeast is localised to the gut, the antibiotics can still act on infection elsewhere in the body.19 Currently, Florey are pursuing a medical food designation for their probiotic product.
In a 2022 proof of concept paper, the team demonstrated in vivo that an engineered strain of Lactococcus lactis could effectively degrade beta-lactam in the gut of mice, without impacting the serum levels of the antibiotic. The paper notes that the beta-lactamase gene does not confer antibiotic resistance to the host strain and is not susceptible to horizontal gene transfer.20
Looking to develop an NGP?
In addition to our world-leading LBP manufacturing solutions, Biose Industrie have fully anaerobically sealed industrial production lines for NGPs with over 600 different strains being manufactured for the different clients around the world!
If you are interested in manufacturing a NGP product, get in touch here.
Sources:
https://isappscience.org/for-scientists/resources/probiotics/
https://pubmed.ncbi.nlm.nih.gov/18936492/
https://www.coherentmarketinsights.com/market-insight/next-generation-probiotics-market-5468#:~:text=Next%20Generation%20Probiotics%20Market%20is,technological%20robustness%2C%20and%20regulatory%20framework.
https://tracxn.com/d/companies/pendulum/__luVW54RO5auUerhcc7Q13foJzCh3cnrhYFPDQPxijj4
https://pmc.ncbi.nlm.nih.gov/articles/PMC8726741/
https://www.prnewswire.com/news-releases/pendulum-therapeutics-introduces-glp-1-probiotic-302087492.html
https://pendulumlife.com/pages/research-clinical-trials
https://tracxn.com/d/companies/the-akkermansia-company/__4YBN0NiDL_m1dVG3gqB8tqCu-XPJDph8X-niTLucL6A/funding-and-investors
https://www.nutraingredients-usa.com/Article/2025/03/06/the-akkermansia-co-on-weight-management-with-akkermansia-muciniphila/#:~:text=The%20Akkermansia%20Company%20launched%20into,decoded%20by%20the%20company’s%20founders.
https://pubmed.ncbi.nlm.nih.gov/31263284/
https://www.nature.com/articles/s41598-021-95738-5
https://pubmed.ncbi.nlm.nih.gov/36502573/
https://pubmed.ncbi.nlm.nih.gov/34819742/
https://pubmed.ncbi.nlm.nih.gov/30643289/
https://pubmed.ncbi.nlm.nih.gov/26742586/
https://pubmed.ncbi.nlm.nih.gov/36177011/
https://pubmed.ncbi.nlm.nih.gov/16672507/
https://clostrabio.com/about.html
https://www.fiercebiotech.com/research/florey-biosciences-spins-out-harvards-wyss-institute-cook-proven-probiotic-medical-foods
https://pubmed.ncbi.nlm.nih.gov/35411114/
[H2] Related Posts
[IMG: Co-culture: the science behind efficient multi-strain bacterial manufacturing]
May 15, 2026
[H3]
Co-culture: the science behind efficient multi-strain bacterial manufacturing

The latest results in microbiome research are speaking
Read More
[IMG: Field Notes from Copenhagen: Our highlights from the 2026 Microbiome Times Partnering Forum Europe]
April 28, 2026
[H3]
Field Notes from Copenhagen: Our highlights from the 2026 Microbiome Times Partnering Forum Europe

By Jean-Baptiste Doucet  |  April 2026
Read More
[IMG: Bacterial count in next-generation probiotics: AFU technology]
March 3, 2026
[H3]
Bacterial count in next-generation probiotics: AFU technology

Classical methodologies and current limitations
Switching from
Read More